Submission

Senate Community Affairs Committee

Inquiry: Commonwealth contribution to former forced adoption policies and practices.

Carol Devine
Coordinator, DES Action Australia-NSW
14 Edmundson Cl
Thornleigh NSW 2120
Ph: 02 98754820
Email: c_devine@bigpond.net.au
Website: www.desnsw.blogspot.com

Summary

This is our organisation's second submission to this inquiry and is pertaining to Forced Adoption Victims who were State Wards and administered DES (diethylstilboestrol) as a lactation suppressant post-delivery. DES was an anti-miscarriage drug prescribed to pregnant women from 1938-1971 (and sometimes beyond). This drug caused serious potentially life threatening problems. Women given DES and their children of that pregnancy are at higher risk of certain types of cancer and reproductive problems. DES exposed people need special vital preventive health care. DES was administered as a lactation suppressant, sometimes as overdose, to Forced Adoption Victims without informed consent. Since lodgement of our previous submission, we hold concern that many thousands of State Ward Forced Adoption Victims, who by law, had no rights to consent to/decline from medical treatments, have been administered DES as a lactation suppressant. For the same reasons outlined in the first submission, there should be expert investigation of cancer incidence and health status of Forced Adoption Victims and State Ward Forced Adoption Victims administered DES as lactation suppressant. There should be an official national public apology to Forced Adoption Victims and State Ward Forced Adoption Victims for the administration of the drug, DES (sometimes as overdose) without informed consent.

Background

Diethylstilboestrol (DES or commonly known as "stilboestrol") is a synthetic oestrogen that was developed to supplement a woman's natural oestrogen production. It was first prescribed in 1938 for women experiencing miscarriages or premature deliveries and originally considered effective and safe. DES was available in the form of tablets, injections, vaginal suppositories (also called pessaries) and sometimes as an ingredient in pregnancy vitamins. In 1971 physicians were advised to stop prescribing DES to pregnant women

because it was linked to a rare vaginal/cervical cancer in female offspring. Since 1971 research has shown:

- Women prescribed DES while pregnant, known as DES mothers, are at 30% increased risk for breast cancer and require annual mammography and clinical breast examinations.
- Women exposed to DES before birth (in the womb), known as DES daughters, are at increased risk for clear cell adenocarcinoma (CCA) of the vagina and cervix, have almost two times increased risk of breast cancer after age 40, reproductive tract structural differences, pregnancy complications and infertility. The risk for developing CCA is about 1:1000 DES daughters. Although DES daughters appear to be at highest risk for clear cell cancer in their teens and early 20s, cases have been reported in the 30-50 age groups [http://obgyn.bsd.uchicago.edu/registry.html#accessions] . This cancer is aggressive; it can be symptomless and is not always detected by the usual Pap smear. It should be detected early. DES daughters require life-long special annual "DES examinations", along with annual mammography and clinical breast examinations. DES daughters also require high-risk care during pregnancy.
- Men exposed to DES before birth (in the womb), known as DES sons, are at risk for non-cancerous epididymal cysts (cysts behind the testicles).

Researchers are still following the health of the DES exposed population to determine whether other health problems occur with age and whether subsequent generations are affected. There is recent research showing menstruation irregularity in DES granddaughters, which hints the possibility of increased risk of infertility. There may be many people who do not know whether they were exposed to DES and some women may not remember taking DES. DES information is important because people who were exposed must be vigilant about their own health care – to detect cancers early, demand high risk obstetric care when pregnant and factor in their exposure when making decisions about HRT use. It is as much part of a person's medical history as a family history toward heart disease or diabetes.

The Adverse Drug Reactions Unit of the Therapeutic Goods Administration (TGA) has data of 18 case reports of DES associated cancer. The failure to report cases has been acknowledged, thus rendering the TGA's database unreliable. There has also been refusal by the TGA to complete regular reciprocal cross-checks of Australian cases that have been reported to the International DES Registry, held in Chicago, USA.

Since providing the estimate of DES exposure in Australia in our organisation's first submission, we have been informed of further DES-type cancer reports by the Australian Institute of Health and Welfare. We have also adjusted our estimate to update the estimate figure to year 2010. Our organisation can now estimate there are up to 740,000 DES daughters, DES mothers and DES sons in Australia.

In 2004 the TGA issued a media release about DES gaining nation-wide media attention. However, this media release contained information mistakenly stating that the increased cancer risks for DES daughters had now passed and that DES daughters no longer require their special annual "DES examinations" for their life-saving cancer prevention. In lobbying government, the organisation DES Action Australia-NSW eventually required legal assistance

to ensure that a media release with correct information was issued by the TGA. In 2008 the TGA issued a further media release with information that DES daughters require life-long follow-up with annual DES examinations. Unfortunately, this 2008 media release did not receive nation-wide media attention.

Due to the time lapse, doctors are unable to track down Australians exposed to DES. It cannot be presumed that doctors have already alerted affected patients about their DES exposure. There has been no public health education campaign by any Australian government to help alert the many DES exposed Australians who are still oblivious to the fact of their exposure, unaware of the harmful effects of DES, and unaware of the special health care they require, including their special vital cancer preventive health care. The public's response to DES Action Australia-NSW following intermittent media attention to DES exposure over the years shows that the health of DES exposed victims has been neglected due to the absence of prominent public information about DES - information which would have prompted earlier access to their rightful health care. Since the 1990s the Australian government has continued to advise DES Action Australia-NSW that raising public awareness of DES could create unnecessary anxieties for women who may not know if they have been exposed to DES.

In 2001 the USA Centers for Disease Control launched the first national public education campaign to educate the US public and physicians about DES (www.cdc.gov/des). The US campaign launch included an extensive media campaign across USA. Australian government information about DES is buried in websites, significantly decreasing the chance that the population would become aware in the first instance that there is any health problem associated with DES. It is the opinion of DES Action Australia-NSW that it is the right of Australians to be informed of the possibility of having been exposed to this dangerous drug. Accordingly, lobbying efforts over the past 5 years have been directed to the Australian government towards ensuring the promotion of information about DES exposure directly to the public in health programs. The situation remains that many people are suffering the effects of DES exposure, without knowing why and what they can do about it.

DES Usage as Lactation Suppressant

DES was approved for usage as a lactation suppressant (to help dry up breast milk) in 1941. In 1968 research showed this DES usage to have risk of thrombosis (blood clot) and pulmonary embolism (blood clot in the lung). This usage was not withdrawn until 1978. It was mainly given in the form of tablets, but was also available as injections and may have been given in liquid oral form. We have received anecdotal reports of its availability for usage in injection form in maternity units and hospitals in the 1980s. There is literature stating that DES principally relieves breast engorgement when lactation commences and will only reduce the milk supply in some cases. It is stated, too, that warm compresses applied to the breasts are also effective. To date, there has been no further research to study the possibility of other adverse effects of DES given as a lactation suppressant.

Administration of DES to State Ward Forced Adoption Victims

Our organisation has received one phone call from a State Ward Forced Adoption Victim. This woman was administered DES as a lactation suppressant post-delivery without having

any legal rights to consent to/decline from the administration of DES. The Survey of 2006-2007 by the organisation Care leavers of Australia Network (CLAN) (www.clan.org.au/images/CLAN_Survey_Results.pdf) shows that 41% of the 212 women surveyed who were State Wards had teenage pregnancies. With the estimate that there were 500,000 State Wards in Australia in the 20th century, it can be estimated that up to 100,000 State Wards have been administered DES as a lactation suppressant as an enforced non-consensual drug administration.

The Role of the Commonwealth in the Practice of DES Usage in State Ward Forced Adoption Victims

Our organisation has anecdotal information of a survey in government records showing approximately 80% incidence of breast/cervical/ovarian cancers among a group of 120 Forced Adoption Victims, members of organisation Origins NSW. With this extraordinarily high incidence, there would also be concerns for the welfare of State Ward Forced Adoption Victims. The Commonwealth has a role in the above matter and a duty of care in addressing this issue.

The Potential Role of the Commonwealth

The potential role of the Commonwealth now goes beyond that outlined in our organisation's previous submission. The above circumstances warrant an official nation-wide investigation by experts of the health status (including cancer incidence) of Forced Adoption Victims and State Ward Forced Adoption Victims who were administered DES as a lactation suppressant. In particular, the reported over-zealous usage of the dangerous drug, DES, by way of **overdoses**, should be investigated for the possibility of causing adverse effects. This investigation should include a systematic comparison of DES dosages given to married women for the suppression of lactation, and any possible adverse effects on these women.

Forced Adoption Victims and State Ward Forced Adoption Victims who were given DES in this manner should be informed of investigation results and of any necessary associated health care measures. Accordingly, married women given DES as lactation suppressant should be informed of any adverse effects of DES and any associated health care required. As remediation, there should be an official national public apology to Forced Adoption Victims and State Ward Forced Adoption Victims for the administration of DES, sometimes as an overdose, without informed consent.